The treatment of patients with infection secondary to carbapenem-resistant Acinetobacter baumannii with emerging cefiderocol resistance remains challenging and unclear. We present a case of in vivo emergence of pandrug-resistant A baumannii that was successfully treated with the compassionate use of investigational sulbactam-durlobactam-based antibiotic regimen. We also performed a longitudinal genomic analysis of the bacterial isolates and showed the development of resistance and genetic mutations over time.
Keywords: acinetobacter baumannii; antimicrobial resistance; carbapenemresistant acinetobacter baumannii; multiple drug-resistant bacteria; sulbactam-durlobactam.
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.